ABT
The deal is doing the math thing
Abbott Laboratories opened April 16 with a little less swagger than it probably wanted. The company cut its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from $5.55 to $5.80, and the market immediately noticed the smell of dilution in the room.
Why the forecast fell
The culprit is Abbott’s $21 billion acquisition of Exact Sciences Corp., which is now expected to shave about 20 cents off earnings. That’s the kind of accounting reality check that can turn a “strategic growth move” into a short-term headache for shareholders.
Investors are not exactly sending thank-you notes
Abbott also said first-quarter profit came in at $1.08 billion, down 18.7% from a year ago. So even if the Exact deal looks smart on the whiteboard, the near-term optics are rough: lower guidance, softer profits, and a stock that’s already reacting like it read the fine print.
Big picture
For investors, this is the classic M&A tradeoff — buy growth now, explain the earnings pain later. If Exact helps Abbott build a bigger cancer screening business, the long game may still make sense. But in the short run, Wall Street is paying attention to the diluted EPS, not the PowerPoint.